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Embryonic stem cells (ESCs) are prone to differentiation in culture, suggesting that maintenance of the plu-
ripotent state must be actively induced. In a recent issue of Nature, Ying et al. (2008) use soluble small mol-
ecules to inhibit pro-differentiation signals and reveal ESC self-renewal as a default cell fate.The hallmark of embryonic stem cells
(ESCs) is that they self-renew as undiffer-
entiated cells while maintaining their pluri-
potency—the ability to give rise to all the
tissues of the body. Defining the signaling
pathways and gene networks that control
these essential properties is a major chal-
lenge. Equally important for therapuetic
applications is learning how to precisely
manipulate this circuitry with small mole-
cules that circumvent the use of animal
products like serum and growth factors.
A recent paper in Nature from Austin
Smith’s group (Ying et al., 2008) makes
important strides toward achieving these
goals.
Mouse ESCs are routinely cultured in
the presence of both leukemia inhibitory
factor (LIF), an antidifferentiation cyto-
kine, and fetal bovine serum (Chambers
and Smith, 2004). Several years ago, the
active ingredient within serum was identi-
fied as the growth factor BoneMorphoge-
netic Protein (BMP) (Ying et al., 2003). In
serum-free, chemically-defined culture
medium, such as a mixture of the com-
mercially available N2 and B27 supple-
ments, recombinant LIF and BMP4 to-
gether sustain ESC self-renewal and
pluripotency. ESCs cultured in this way
contribute to chimeras that show germ
line transmission, the gold standard test
for pluripotency. These findings have led
to the prevailing model that these two ex-
trinsic signals shield mouse ESCs from
making the decision to differentiate and
ensure their continuous self-renewal.
One differentiation signal blocked by
LIF and BMP4 is Fibroblast Growth Factor
4 (FGF4). FGF4, a potent neuralizing fac-
tor, and its intracellular effector, mitogen
activated kinase (ERK), are abundant in
mouse ESCs (Kunath et al., 2007; Stavri-
dis et al., 2007). Ying et al. hypothesized
that LIF and BMP4 collaborate down-
stream of FGF to constrain differentiation,
which led them to investigate the interre-
lationship of FGF, LIF, and BMP4 signal-
ing. Their efforts revealed that by manipu-
lating FGF signaling, ESCs will grow
without the need for exogenous BMP4
and LIF. The authors used a cocktail of se-
lective small-molecule inhibitors to modu-
late FGF signaling. They first observed
that inhibition of FGF signaling obviates
the need for BMP4 in defined N2B27 cul-
ture medium. ESCs remained sensitive to
LIF withdrawal in the presence of the FGF
inhibitors, as the cultures exhibited re-
duced growth and viability. Quite remark-
ably, however, FGF inhibition permits ex-
pansion of ESCs over multiple passages
with persistent expression of the cardinal
markers of pluripotency, Oct4 andNanog.
These results suggest that mouse ESC
self-renewal can be recast as an exercise
in avoiding FGF-induced differentiation
rather than direct promotion by combined
LIF and BMP4 signaling.
Similar to FGF, canonical WNT signal-
ing operates in undifferentiated mouse
ESCs (Sato et al., 2004; Ying et al.,
2008). WNT ligand binding to cell surface
receptors results in the downstream inac-
tivation of Glycogen Synthase Kinase
(GSK) and translocation of b-catenin to
the nucleus. There, b-catenin complexes
with the LEF/TCF family of DNA-binding
proteins to regulate target gene transcrip-
tion. The Brivanlou group previously re-
ported that BIO, a specific pharmaco-
logical inhibitor of GSK3, maintains
pluripotency and self-renewal in mouse
ESCs cultured in the presence of serum
for short periods (Sato et al., 2004). Ying
et al. therefore investigated the role of
WNT signaling in their defined N2B27 cul-
ture system. In contrast to previous work,
BIO treatment alone leads to decreased
ESC viability. The authors nevertheless
pursued a second, more selective GSK3
inhibitor, CHIR99021. ESC survival im-
proves with CHIR99021, but cultures in-
variably succumb to differentiation. How-
ever, a combination of two FGF pathway
inhibitors (SU5402 and PD184352) and
CHIR99021—the trio is designated 3i—
allows highly efficient expansion of undif-
ferentiated ESCs that express Oct4 and
Nanog. When plated as individual cells,
3i treatment even results in greater num-
bers of Oct4-positive colonies than stan-
dard culture in LIF and BMP4. As a rigor-
ous test of the activity of the inhibitor
cocktail, mouse ESC lines were derived
directly from blastocysts cultured in 3i.
The utility of 3i is further bolstered by the
successful isolation of ESC lines from
the CBA mouse strain, previously recalci-
trant to standard derivation techniques.
Taken together, these results demon-
strate that the simple 3i mixture emanci-
pates mouse ESCs from the classic cul-
ture requirements of LIF and BMP/serum.
The use of small-molecule inhibitors rai-
ses standard concerns about off-target
effects. To allay these fears, Ying et al.
combined biochemical and genetic ap-
proaches to confirm the specificity of 3i.
If FGF inhibition can sustain self-renewal
and pluripotency, then eliminating the
endogenous production of FGF4 should
yield similar results. Indeed, Fgf4 null
ESCs are able to expand continuously
when grown in culture medium sup-
plemented with the GSK inhibitor
CHIR99021. Similarly, Erk2 null ESCs
can be maintained in CHIR99021, al-
though optimal expansion requires the
additional suppression of ERK1. To con-
firm that GSK3 is indeed the target of
CHIR99021, a mouse ESC line in which
both theGsk3a andGsk3b genes were in-
activated was investigated (Doble et al.,
2007). These cells differentiate rapidly in
N2B27 medium. With the addition of FGF
inhibitors, differentiation is suppressed
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wild-type cells. Despite this finding, sev-
eral questions remain with regard to
WNT signaling. What are the downstream
consequences of elevated (approximately
3-fold) WNT signaling? It is noteworthy
that recombinant WNT3A is not function-
ally equivalent to CHIR99021, and endog-
enous expression of Wnt3 and Wnt8 is
low in wild-type ESCs (Lindsley et al.,
2006). Thus, GSK3 inhibition might result
in downstream transcriptional outputs
that are LEF/TCF-independent. This pos-
sibility could be further examined in ESCs
in which the b-catenin pool is artificially
stabilized. The authors posit that lowered
GSK3 levels globally impact the ‘‘energy
level’’ within a given stem cell, accommo-
dating the dramatic loss of activated ERK
and its role in basic cellular processes.
Whither LIF? Since its identification two
decades ago, LIF has been considered
a guardian of ESC fate, with most models
emphasizing the requirement for LIF-me-
diated activation of STAT3 to maintain
self-renewal and pluripotency (Chambers
and Smith, 2004). For example, it is im-
possible to isolate ESC lines that overex-
press a dominant-interfering STAT3 mu-
tant (Niwa et al., 1998). Ying et al.,
however, succeeded in isolating Stat3-
deficient ESC lines using their defined 3i
medium. When exposed to LIF and se-
rum, these cells expectedly fail to activate
the STAT3 target gene Socs3 and rapidly
differentiate. These findings demonstrate
unequivocally that LIF signaling is entirely
dispensable. With its elimination as a nec-
essary extrinsic signal for self-renewal,
mouse ESCs can now be studied in their
experimentally induced ‘‘ground state,’’
where their basic, intrinsic mechanisms
of self-duplication and pluripotency are
revealed in a neutralized tissue-culture
environment and await precise character-
ization.
One practical outcome of this work is
the possibility that mouse ESC culture
and derivation platforms can be simplified
and standardized with 3i medium. This
would certainly be welcomed as a cost-
effective solution to the considerable ex-
penses of fetal bovine serum and re-
combinant LIF. Lastly, the inevitable
question will arise: What about human
ESCs? It is important to emphasize that
human and mouse ESCs are nonequiva-
lent with regard to their culture require-
ments, with human ESCs mostly depen-
dent upon extrinsic FGF and Activin/
Nodal signaling for their propagation (Val-
lier et al., 2005). Although 3i will likely trig-
ger rapid differentiation of human ESCs,
the strategy developed by Ying et al.
certainly emboldens current screening
efforts aimed at identifying small mole-
cules that will equally sustain human
ESC self-renewal and, importantly, facili-
tate scale-up for the production of
clinically relevant cell types.
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Ex vivo hematopoiesis from embryonic sources offers exciting promises in basic research and medicine. In
this issue of Cell Stem Cell, Ledran et al. (2008) describe human embryonic stem cell (hESC)-derived hema-
topoiesis, while Taoudi et al. (2008) define the origin of definitive hematopoietic stem cells (HSCs) from the
mouse aorta-gonad-mesonephros (AGM) region.
While regenerative medicine in the form of
HSC transplantation has been used to
successfully treat various disorders, sig-
nificant limitations remain. Understanding
hematopoietic ontogeny and developing
efficient methods for ex vivo derivation
of hematopoietic cells will significantly
facilitate existing and novel therapeutic
strategies. In this issue of Cell Stem Cell,
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